How tech supports patients and expands the potential of clinical trials

AI, and technology more broadly, dominates headlines, and as someone working at a health technology company on the cutting edge of clinical research, I'm often asked how these advancements tangibly impact healthcare and people’s experience of their disease and treatments.

At Medidata, we're dedicated to answering this question by powering smarter treatments and improving health outcomes through digital solutions that support clinical trials. With over 25 years of experience, we've observed that participants in clinical trials are typically informed and interested in the mechanics, goals, and milestones of the research they’re involved in.

However, if patients feel overburdened by the day-to-day activities of clinical trials—such as long-distance travel, extensive record-keeping, financial strain, time off work, or childcare—they are much more likely to drop out. When this happens, it represents a broken bond with the patient,a failure in the research process, and a significant loss of time and money for the trial sponsors.

This is precisely where technology can make a meaningful impact for both patients and clinical researchers throughout the entire clinical trial journey, from recruitment to in-trial activities and ultimately, getting new treatments to market. The future of clinical research for new medical breakthroughs hinges on the life sciences industry reducing friction, establishing trust, and empowering patients to remain engaged in their clinical trials from start to finish.

The Role of eCOA Technologies

My main focus at Medidata is on electronic clinical outcome assessment (eCOA) technologies. These tools provide organizations running clinical trials and clinical researchers with a more comprehensive understanding of how a treatment impacts individual patients. They offer detailed insights into how patients feel about their condition and treatment and form the backbone of decentralised clinical trials (DCT) solutions.

eCOA technologies achieve this by providing patients a central location to interact with and complete all their clinical trial tasks, whether on a smartphone device that’s been provided to them for the trial, via an app they install on their own device, or a web browser. Patients can access eCOA questionnaires, review consent documents, request and attend a telemedicine visit, interact with wearable sensors, and complete clinical trial site visits. Whether smartphone-based or web-based, these platforms are designed to deliver crucial information to patients at the right time. This ensures consistent, tailored access to their trial responsibilities without the burden of switching between platforms or logging into different sites unnecessarily. This technology also allows for continued scalability, which is vital for accelerating the modernization of clinical trials.

One of the biggest technological shifts in recent years has been the adoption of Bring Your Own Device (BYOD) strategies. While there were initial concerns within the life sciences industry regarding data comparability and operational logistics, BYOD has proven to be both reliable and effective. Today, it's a significant part of what we call the "silent revolution" in clinical trials—a move towards greater accessibility and patient choice.

eCOA technologies have been instrumental in this shift towards patient flexibility and comfort in the modern clinical trial process. A great example is the remote six-minute walk test: participants wear a sensor at home and follow instructions provided by their eCOA solution. Data is then collected and fed back to the clinical trial study team in near real-time for analysis. We're seeing results comparable to the "gold standard" methodology collected on-site at a clinic or hospital, which could be many miles from a patient's home. Similarly, eConsent platforms allow patients to remotely review and sign consent forms, removing the inconvenience of traveling to a clinical trial site.

The Human-Centered Future of AI in Trials

At its best, AI can automate tedious manual tasks, surface data, insights and actionable information at the most pertinent times, and make digital tools feel more responsive and personal. However, AI should always complement, not replace, human-centered design, and robust privacy safeguards must be built in from the start. This begins with co-design, bringing patients into the room early to shape tools that genuinely reflect their lived experience. It also means going beyond regulatory metrics and investing in platforms that track engagement, satisfaction, and usability in meaningful ways. Medidata's AI Everywhere Strategy has enabled us to responsibly expand AI's role across clinical and operational decision-making, designed to accelerate planning, streamline execution, and reduce the burden for patients, sites, and sponsors.

While significant progress has been made towards patient-focused trials, transitioning to this new process can be challenging for many organizations. Although eConsent platforms have garnered considerable interest, the added complexity of global clinical trials has so far hindered their widespread adoption. The real hurdle, however, isn't the technology itself, which is more accessible and user-friendly now than ever before. Instead, it's the internal change management across IRBs, clinical sites and pharmaceutical companies required to truly prioritize patients and integrate new technological processes into organizations. Change demands a shift in mindset, not just the integration of new tools.

For organizations that successfully engage with the modern trial, it's crucial to understand the need to completely restructure how trials are designed. This means engaging with patients even before protocol design begins, and finding ways to foster ongoing communication with them throughout a trial and beyond, to be more inclusive, flexible, and tech-enabled.

Different therapy areas have adapted to this modernization process in various ways. Rare and complex diseases, such as those relating to the Central Nervous System (CNS), have often led the way in patient-centricity due to the urgency and complexity of these conditions. Medidata supports organizations running clinical trials through these challenges, providing strategic advice to clinical researchers through our Experiences Strategy. Our approach is based on insights and data from over 36,000 clinical trials and 11 million patients—one of the largest clinical trial datasets in the life sciences industry.

Ultimately, modernizing clinical trials isn't just about integrating technology; it's about rethinking the entire patient journey. It's about asking how trials can fit into a patient’s life, rather than asking patients to fit into a trial. With this approach, and with the right tools, we can build a future where trials are more inclusive, more efficient, and most importantly, more human. To find out more, please visit www.Medidata.com